Journal of Traditional Chinese Medicine >
Identifying the effective combination of acupuncture and traditional Chinese medicinal herbs for postmenopausal osteoporosis therapy through studies of their molecular regulation of bone homeostasis
Received date: 2022-11-11
Accepted date: 2023-04-08
Online published: 2023-09-04
Worldwide, as the population age, osteoporosis is becoming increasingly common, and osteoporotic fractures have a significant economic burden. Postmenopausal women are the most susceptible to developing osteoporosis and the most critical time to prevent it is during the perimenopausal and early menopausal years. In this regard, we hypothesize rational combination of acupuncture and Traditional Chinese Medicine (TCM) in the form of herbal extract could prevent osteoporosis in women. Estrogen deficiency during menopause causes low-level inflammation that stimulates the formation of osteoclasts, the bone-resorbing cells, and simultaneously inhibits the viability and function of osteoblasts, the bone-forming cells. The most potent inflammatory cytokine in skeletal homeostasis is the receptor activator of nuclear factor kappa B ligand (RANKL) that stimulates osteoclast function. Conversely, the canonical Wnt pathway is essential for osteoblastogenesis and bone formation, and estrogen deficiency leads to diminished functioning of this pathway. TCM and acupuncture could target the RANKL and the Wnt pathway in favorable ways to prevent the accelerated bone loss experienced during the early menopausal stage and promote the gain in bone mass in postmenopausal women. In this review, we propose a rational combination of specific TCM and acupuncture targeting those signaling molecules/pathways by the drugs that are in clinical use for the treatment of postmenopausal osteoporosis. Our rational approach revealed that Danshen (Radix Salviae Miltiorrhizae) could exert a synergistic effect with acupuncture. We then propose a translational path for developing the putative combination in women with postmenopausal osteoporosis to curtail the risk of osteoporotic fractures.
Key words: medicine, traditional; osteogenic; anti-resorptive; review
Ping REN , Quanwu WANG , Wei BAI , Miao SUN , Zheling LIU , Ming GAO , Liang WANG , Bo PENG , Liguang XU . Identifying the effective combination of acupuncture and traditional Chinese medicinal herbs for postmenopausal osteoporosis therapy through studies of their molecular regulation of bone homeostasis[J]. Journal of Traditional Chinese Medicine, 2024 , 44(1) : 212 -219 . DOI: 10.19852/j.cnki.jtcm.20230904.006
| 1. | Neer RM, Investigators S. Bone loss across the menopausal transition. Ann N Y Acad Sci 2010; 1192: 66-71. |
| 2. | Idelevich A, Baron R. Brain to bone: what is the contribution of the brain to skeletal homeostasis? Bone 2018; 115: 31-42. |
| 3. | Cai X, Jiang Y, Lin M, et al. Ultrasound-responsive materials for drug/gene delivery. Front Pharmacol 2019; 10: 1650. |
| 4. | Kenkre JS, Bassett J. The bone remodelling cycle. Ann Clin Biochem 2018; 55: 308-327. |
| 5. | Zhu X, Zheng H. Factors influencing peak bone mass gain. Front Med 2021; 15: 53-69. |
| 6. | Trivedi R, Goswami R, Chattopadhyay N. Investigational anabolic therapies for osteoporosis. Expert Opin Investig Drugs 2010; 19: 995-1005. |
| 7. | Sharan K, Siddiqui JA, Swarnkar G, Maurya R, Chattopadhyay N. Role of phytochemicals in the prevention of menopausal bone loss: evidence from in vitro and in vivo, human interventional and pharma-cokinetic studies. Curr Med Chem 2009; 16: 1138-57. |
| 8. | Dhar MK, Koul A, Kaul S. Farnesyl pyrophosphate synthase: a key enzyme in isoprenoid biosynthetic pathway and potential molecular target for drug development. N Biotechnol 2013; 30: 114-23. |
| 9. | Rogers MJ, Crockett JC, Coxon FP, Monkkonen J. Biochemical and molecular mechanisms of action of bisphosphonates. Bone 2011; 49: 34-41. |
| 10. | Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998; 95: 3597-602. |
| 11. | Pangrazio A, Cassani B, Guerrini MM, et al. RANK-dependent autosomal recessive osteopetrosis: characterization of five new cases with novel mutations. J Bone Miner Res 2012; 27: 342-51. |
| 12. | Janssens K, de Vernejoul MC, de Freitas F, Vanhoenacker F, Van Hul W. An intermediate form of juvenile Paget's disease caused by a truncating TNFRSF11B mutation. Bone 2005; 36: 542-8. |
| 13. | Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009; 361: 756-65. |
| 14. | Meier C, Meinhardt U, Greenfield JR, et al. Serum cathepsin K concentrations reflect osteoclastic activity in women with postmenopausal osteoporosis and patients with Paget's disease. Clin Lab 2006; 52: 1-10. |
| 15. | Gelb BD, Shi GP, Chapman HA, Desnick RJ. Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science 1996; 273: 1236-8. |
| 16. | Hou WS, Bromme D, Zhao Y, et al. Characterization of novel cathepsin K mutations in the pro and mature polypeptide regions causing pycnodysostosis. J Clin Invest 1999; 103: 731-8. |
| 17. | Mukherjee K, Chattopadhyay N. Pharmacological inhibition of cathepsin K: a promising novel approach for postmenopausal osteoporosis therapy. Biochem Pharmacol 2016; 117: 10-9. |
| 18. | Recker R, Dempster D, Langdahl B, et al. Effects of odanacatib on bone structure and quality in postmenopausal women with osteoporosis: 5-year data from the phase 3 long-term odanacatib fracture trial (LOFT) and its extension. J Bone Miner Res 2020; 35: 1289-99. |
| 19. | Bhattacharyya S, Pal S, Chattopadhyay N. Abaloparatide, the second generation osteoanabolic drug: molecular mechanisms underlying its advantages over the first-in-class teriparatide. Biochem Pharmacol 2019; 166: 185-91. |
| 20. | Hamersma H, Gardner J, Beighton P. The natural history of sclerosteosis. Clin Genet 2003; 63: 192-7. |
| 21. | Balemans W, Patel N, Ebeling M, et al. Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. J Med Genet 2002; 39: 91-7. |
| 22. | Bhattacharyya S, Pal S, Chattopadhyay N. Targeted inhibition of sclerostin for post-menopausal osteoporosis therapy: a critical assessment of the mechanism of action. Eur J Pharmacol 2018; 826: 39-47. |
| 23. | Cosman F, Crittenden DB, Adachi JD, et al. Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 2016; 375: 1532-43. |
| 24. | Xu G, Xiao Q, Zhou J, et al. Acupuncture and moxibustion for primary osteoporosis: an overview of systematic review. Medicine (Baltimore) 2020; 99: e19334. |
| 25. | Huang F, Xie Y, Zhao S, Feng Z, Chen G, Xu Y. The effectiveness and safety of acupoint catgut embedding for the treatment of postmenopausal osteoporosis: a systematic review and Meta-analysis. Evid Based Complement Alternat Med 2019; 2019: 2673763. |
| 26. | Wang HD, Chen Z, Inoue I, et al. Effects of electroacupuncture at GB points on markers of osteoporosis and bodyweight in ovariectomised rats. Acupunct Med 2015; 33: 465-71. |
| 27. | Zhang W, Kanehara M, Zhang Y, et al. Acupuncture increases bone strength by improving mass and structure in established osteoporosis after ovariectomy in rats. J Tradit Chin Med 2006; 26: 138-47. |
| 28. | Fan H, Ji F, Lin Y, et al. Electroacupuncture stimulation at CV4 prevents ovariectomy-induced osteoporosis in rats via Wnt-beta-catenin signaling. Mol Med Rep 2016; 13: 2485-91. |
| 29. | Zheng X, Wu G, Nie Y, Lin Y. Electroacupuncture at the governor vessel and bladder meridian acupoints improves postmenopausal osteoporosis through osteoprotegerin/RANKL/RANK and Wnt/ beta-catenin signaling pathways. Exp Ther Med 2015; 10: 541-8. |
| 30. | He J, Yang L, Qing Y, He C. Effects of electroacupuncture on bone mineral density, oestradiol level and osteoprotegerin ligand ex-pression in ovariectomised rabbits. Acupunct Med 2014; 32: 37-42. |
| 31. | Peng Z, Xu R, You Q. Role of Traditional Chinese Medicine in bone regeneration and osteoporosis. Front Bioeng Biotechnol 2022; 10: 911326. |
| 32. | Yan FF, Liu Y, Liu YF, Zhao YX. Herba Epimedii water extract elevates estrogen level and improves lipid metabolism in postmenopausal women. Phytother Res 2008; 22: 1224-8. |
| 33. | Qian G, Zhang X, Lu L, Wu X, Li S, Meng J. Regulation of Cbfa1 expression by total flavonoids of Herba epimedii. Endocr J 2006; 53: 87-94. |
| 34. | Liang W, Lin M, Li X, et al. Icariin promotes bone formation via the BMP-2/Smad4 signal transduction pathway in the hFOB 1.19 human osteoblastic cell line. Int J Mol Med 2012; 30: 889-95. |
| 35. | Sun LJ, Li C, Wen XH, et al. Icariin stimulates hFOB 1.19 osteoblast proliferation and differentiation via OPG/RANKL mediated by the estrogen receptor. Curr Pharm Biotechnol 2021; 22: 168-75. |
| 36. | Zhang D, Fong C, Jia Z, Cui L, Yao X, Yang M. Icariin stimulates differentiation and suppresses adipocytic transdifferentiation of primary osteoblasts through estrogen receptor-mediated pathway. Calcif Tissue Int 2016; 99: 187-98. |
| 37. | Huang Y, Liu X, Zhao L, Li F, Xiong Z. Kidney tissue targeted metabolic profiling of glucocorticoid-induced osteoporosis and the proposed therapeutic effects of Rhizoma Drynariae studied using UHPLC/MS/MS. Biomed Chromatogr 2014; 28: 878-84. |
| 38. | Xu T, Wang L, Tao Y, Ji Y, Deng F, Wu XH. The function of naringin in inducing secretion of osteoprotegerin and inhibiting formation of osteoclasts. Evid Based Complement Alternat Med 2016; 2016: 8981650. |
| 39. | Lu L, Wang Z, Zhang H, Liu T, Fang H. Drynaria fortunei improves lipid profiles of elderly patients with postmenopausal osteoporosis via regulation of Notch1-NLRP3 inflammasome-mediated inflammation. Gynecol Endocrinol 2022; 38: 176-80. |
| 40. | Pang WY, Wang XL, Mok SK, et al. Naringin improves bone properties in ovariectomized mice and exerts oestrogen-like activities in rat osteoblast-like (UMR-106) cells. Br J Pharmacol 2010; 159: 1693-703. |
| 41. | Swarnkar G, Sharan K, Siddiqui JA, et al. A naturally occurring naringenin derivative exerts potent bone anabolic effects by mimicking oestrogen action on osteoblasts. Br J Pharmacol 2012; 165: 1526-42. |
| 42. | Song SH, Zhai YK, Li CQ, et al. Effects of total flavonoids from Drynariae Rhizoma prevent bone loss in vivo and in vitro. Bone Rep 2016; 5: 262-73. |
| 43. | Wong KC, Pang WY, Wang XL, et al. Drynaria fortunei-derived total flavonoid fraction and isolated compounds exert oestrogen-like protective effects in bone. Br J Nutr 2013; 110: 475-85. |
| 44. | Hu Y, Mu P, Ma X, Shi J, Zhong Z, Huang L. Rhizoma drynariae total flavonoids combined with calcium carbonate ameliorates bone loss in experimentally induced Osteoporosis in rats via the regulation of Wnt3a/beta-catenin pathway. J Orthop Surg Res 2021; 16: 702. |
| 45. | Gan D, Xu X, Chen D, Feng P, Xu Z. Network pharmacology-based pharmacological mechanism of the Chinese Medicine Rhizoma drynariae against osteoporosis. Med Sci Monit 2019; 25: 5700-16. |
| 46. | Wang L, Ma R, Liu C, et al. Salvia miltiorrhiza: a potential red light to the development of cardiovascular diseases. Curr Pharm Des 2017; 23: 1077-97. |
| 47. | Guo Y, Li Y, Xue L, et al. Salvia miltiorrhiza: an ancient Chinese herbal medicine as a source for anti-osteoporotic drugs. J Ethnopharmacol 2014; 155: 1401-16. |
| 48. | Panwar P, Xue L, Soe K, et al. An ectosteric inhibitor of cathepsin k inhibits bone resorption in ovariectomized mice. J Bone Miner Res 2017; 32: 2415-30. |
| 49. | Yang W, Han J, Gong S, Zhao J, Yu T, Ma J. Cryptotanshinone suppressed postmenopausal osteoporosis by preventing RANKL-mediated osteoclastogenesis against kidney injury. Evid Based Complement Alternat Med 2022; 2022: 2821984. |
| 50. | Qin H, Zhao W, Jiao Y, et al. Aqueous extract of Salvia miltiorrhiza Bunge-Radix Puerariae herb pair attenuates osteoporosis in ovariectomized rats through suppressing osteoclast differentiation. Front Pharmacol 2020; 11: 581049. |
| 51. | Park B, Song HS, Kwon JE, et al. Effects of Salvia miltiorrhiza extract with supplemental liquefied calcium on osteoporosis in calcium-deficient ovariectomized mice. BMC Complement Altern Med 2017; 17: 545. |
| 52. | Buist DS, LaCroix AZ, Manfredonia D, Abbott T. Identifying postmenopausal women at high risk of fracture in populations: a comparison of three strategies. J Am Geriatr Soc 2002; 50: 1031-8. |
/
| 〈 |
|
〉 |